Which is why our mission is to make innovative medicines available at radically lower prices.
See how we are raising awareness of financial toxicity and working to make innovative new medicines available at radically lower costs.
It all starts with our name.
The EQ in EQRx stands for a lot of things. But at its heart, our name stands for our societal contract to bring the best of today’s innovation to patients at radically lower prices.
EQRx’s radically lower cost medicines could dramatically increase global access for cancer patients and tackle the growing cost burden that befalls them.
Our radically new model brings together every aspect of the healthcare system through non-traditional partnerships that bring a new level of transparency & collaboration.
We’re starting in lung cancer with two innovative therapies that have now published Phase 3 clinical trial results.
Our Phase 3 Trial data of aumolertinib in first-line treatment of patients with stage III or IV non-small cell lung cancer (NSCLC) with the most common types of EGFR mutations presented at ASCO 2021Read the results announcement
Our Phase 3 data of sugemalimab, an anti-PD-L1 antibody, in stage III non-small cell lung cancer (NSCLC)Read the results announcement
Updated data from Phase 3 study of sugemalimab in Stage IV NSCLC presented at WCLC 2021Read the results announcement
Results from Stage III and Stage IV studies suggest sugemalimab is a promising potential treatment option in a broad range of NSCLC patients at ESMO 2021Read the results announcement